{"title":"Invention of Enmetazobactam: An Indian Triumph in Antimicrobial Drug Discovery.","authors":"Maneesh Paul-Satyaseela","doi":"10.1021/acsinfecdis.4c00982","DOIUrl":null,"url":null,"abstract":"<p><p>The discovery of antimicrobials was an inflection point in human existence since it contributed enormously to the extension of the human lifespan. Among others, the invention of Enmetazobactam marks a significant milestone in the field of antimicrobial development, especially for India. It is a novel beta-lactamase inhibitor invented by scientists at Orchid Pharma in Chennai, India, and has garnered international attention for its potential to address antimicrobial resistance. It became the first new chemical entity invented in India, clinically developed by Allecra Therapeutics GmbH, to be approved by the U.S. Food & Drug Administration, with additional approvals from the European Medical Agency, the U.K.'s Medicine & Healthcare Products Regulatory Agency, and the Drug Controller General of India.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.4c00982","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The discovery of antimicrobials was an inflection point in human existence since it contributed enormously to the extension of the human lifespan. Among others, the invention of Enmetazobactam marks a significant milestone in the field of antimicrobial development, especially for India. It is a novel beta-lactamase inhibitor invented by scientists at Orchid Pharma in Chennai, India, and has garnered international attention for its potential to address antimicrobial resistance. It became the first new chemical entity invented in India, clinically developed by Allecra Therapeutics GmbH, to be approved by the U.S. Food & Drug Administration, with additional approvals from the European Medical Agency, the U.K.'s Medicine & Healthcare Products Regulatory Agency, and the Drug Controller General of India.
期刊介绍：
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
